Personalis (PSNL) AI Stock Analysis

• Market Cap: $638.06M
• Dividend Yield: N/A
• Average Volume (3M): 1.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: -21.02%
• EPS Growth: 47.74%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.24
• Shares Outstanding: 88,804,350
• 10 Day Avg. Volume: 1,189,853
• 30 Day Avg. Volume: 1,261,665
• PEG Ratio: 0.11
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 4.05
• P/FCF Ratio: -7.33
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 6.80
• Enterprise Value/Gross Profit: 25.49
• Enterprise Value/Ebitda: -7.19
• 1Y Price Target: $10.50
• Price Target Upside: 51.52% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.96
• Revenue Forecast (FY): $70.87M

• Rating: 43 Neutral
• Price Target: $6.50 ▼(-6.20% Downside)

Personalis is facing significant financial and valuation challenges, with declining revenue and profitability issues being the most impactful factors. Technical analysis indicates a bearish trend, though there is potential for a reversal. The earnings call provided some positive insights into clinical adoption and strategic partnerships, but these are overshadowed by financial headwinds.

Positive Factors

Clinical Test Growth

The significant growth in clinical test volumes indicates strong market adoption and positions Personalis well in the expanding precision oncology market.

Strong Financial Position

A robust cash position provides financial stability and flexibility to invest in growth initiatives and navigate potential market challenges.

Partnership Success

Successful partnerships enhance Personalis's market reach and credibility, supporting long-term revenue growth and innovation.

Negative Factors

Revenue Decline

A significant revenue decline indicates challenges in maintaining growth momentum, impacting financial performance and market confidence.

Gross Margin Decrease

Falling gross margins suggest inefficiencies and increased costs, which could pressure profitability and limit reinvestment capacity.

Biopharma Revenue Challenges

Challenges in biopharma revenue highlight dependency on external projects, which can lead to volatility and affect long-term revenue stability.

Personalis Business Overview & Revenue Model

Company Description

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

How the Company Makes Money

Personalis generates revenue primarily through its genomic sequencing services, which are utilized by pharmaceutical companies, academic institutions, and healthcare providers. The company offers a range of products and services, including whole exome and custom gene panel sequencing, as well as bioinformatics analysis. Key revenue streams include contracts with pharmaceutical companies for companion diagnostics and clinical trials, where Personalis provides genomic insights to support drug development. Additionally, the company has established partnerships with leading cancer centers and research institutions, contributing to its earnings through collaborative research projects and service agreements. Personalis also benefits from reimbursement for its services through health insurance providers, further enhancing its revenue model.

Personalis Financial Statement Overview

Summary

Personalis faces significant financial challenges, with declining revenue, negative profitability, and cash flow issues. Despite a strong equity position, the company struggles with efficiency and profitability, as reflected in negative margins and ROE. Improvements in revenue growth and operational efficiency are crucial for financial stability and growth.

Income Statement

Personalis has faced declining revenue growth, with a negative growth rate of -13.96% in the TTM period. The company struggles with profitability, as evidenced by negative net profit margins (-135.30%) and EBIT margins (-95.49%). The gross profit margin is low at 7.20%, indicating challenges in covering operating expenses. Overall, the income statement reflects significant financial challenges and declining performance.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.19, indicating manageable leverage. However, the return on equity is negative at -38.25%, reflecting poor profitability and efficiency in using equity capital. The equity ratio stands at 70.60%, suggesting a strong equity base relative to total assets. Despite a solid equity position, the negative ROE highlights ongoing profitability issues.

Cash Flow

Personalis has a negative operating cash flow, with a coverage ratio of -1.67, indicating insufficient cash generation to cover net income. The free cash flow growth rate is positive at 34.53%, but the free cash flow to net income ratio of 1.09 suggests reliance on external financing. Overall, cash flow challenges persist, with improvements needed in operational cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	69.10M	84.61M	73.48M	65.05M	85.49M	78.65M
Gross Profit	18.43M	26.82M	18.21M	13.35M	31.66M	20.11M
EBITDA	-65.31M	-70.30M	-96.81M	-104.64M	-59.01M	-35.46M
Net Income	-73.88M	-81.28M	-108.30M	-113.31M	-65.23M	-41.28M
Balance Sheet
Total Assets	242.84M	270.27M	225.10M	292.70M	396.53M	244.84M
Cash, Cash Equivalents and Short-Term Investments	150.51M	185.01M	114.18M	167.66M	287.06M	203.29M
Total Debt	41.87M	44.25M	47.73M	48.65M	58.33M	10.99M
Total Liabilities	71.42M	67.31M	95.66M	74.56M	86.23M	49.90M
Stockholders Equity	171.41M	202.96M	129.44M	218.14M	310.30M	194.94M
Cash Flow
Free Cash Flow	-66.17M	-46.75M	-67.17M	-120.13M	-81.91M	-45.90M
Operating Cash Flow	-60.50M	-45.15M	-56.26M	-70.23M	-70.83M	-42.65M
Investing Cash Flow	-34.37M	-35.07M	13.10M	52.54M	-60.07M	-65.14M
Financing Cash Flow	69.04M	114.67M	11.03M	1.37M	169.70M	121.27M

Personalis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.93
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Neutral. The current price of 6.93 is below the 20-day moving average (MA) of 8.99, below the 50-day MA of 7.33, and above the 200-day MA of 5.49, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 36.90 is Neutral, neither overbought nor oversold. The STOCH value of 8.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PSNL.

Personalis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	64 Neutral	$772.00M	13.10	24.11%	―	14.46%	―
CSTL	62 Neutral	$979.28M	―	-2.69%	―	10.15%	-295.52%
FLGT	60 Neutral	$682.89M	―	-4.54%	―	4.31%	69.57%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	51 Neutral	$587.25M	―	-72.52%	―	0.21%	-233.51%
PSNL	43 Neutral	$638.06M	―	-43.69%	―	-21.02%	47.74%
LAB	41 Neutral	$454.57M	-3.72	-24.63%	―	-17.37%	52.28%

Personalis Corporate Events

Personalis Earnings Call: Strategic Gains Amid Revenue Hurdles

Personalis Earnings Call Highlights Strategic Partnerships Amid Revenue Challenges

Personalis Reports Q3 2025 Financial Results

Personalis, Inc., based in Fremont, California, is a leader in advanced genomics for precision oncology, focusing on personalized cancer management through innovative testing solutions. In its third-quarter 2025 financial results, Personalis highlighted significant progress in its “Win-in-MRD” strategy, marked by a substantial increase in clinical test deliveries and strong clinical evidence supporting its NeXT Personal platform for cancer monitoring. Key achievements include a 364% year-over-year growth in clinical test volume, the submission for Medicare coverage for lung cancer, and the launch of a new breast cancer utility study in collaboration with Yale Cancer Center.

Personalis Inc. Advances TNBC Treatment with Innovative ctDNA Study

Personalis Inc. is spearheading a pivotal clinical study titled ‘Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)’. The study aims to evaluate the effectiveness of a circulating tumor DNA (ctDNA) guided test in detecting Molecular Residual Disease (MRD) and its correlation with pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with stage I-III triple-negative breast cancer (TNBC). This research is significant as it seeks to enhance MRD detection and improve disease outcomes for future TNBC patients.

Personalis Secures New VA Contract Task Order

On August 19, 2025, Personalis, Inc. announced a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program, effective September 30, 2025, valued at up to $13.5 million. This order increases the cumulative value of task orders received by Personalis under its contracts with the VA MVP to approximately $225.0 million, highlighting the company’s significant role in this large-scale genomic research initiative.

The most recent analyst rating on (PSNL) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Personalis stock, see the PSNL Stock Forecast page.